

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Synthesis of Oligonucleotides Containing 5,6-Dihydro-5-Azacytosine and 5-Azacytosine at Specific CpG Sites

Amanda J. Goddard^a; Victor E. Marquez^a

^a Laboratory of Medicinal Chemistry, Developmental Therapeutics Program, Division of Cancer Treatment National Cancer Institute, Bethesda, MD

To cite this Article Goddard, Amanda J. and Marquez, Victor E.(1989) 'Synthesis of Oligonucleotides Containing 5,6-Dihydro-5-Azacytosine and 5-Azacytosine at Specific CpG Sites', *Nucleosides, Nucleotides and Nucleic Acids*, 8: 5, 1015 – 1018

To link to this Article: DOI: 10.1080/07328318908054266

URL: <http://dx.doi.org/10.1080/07328318908054266>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.


The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.


SYNTHESIS OF OLIGONUCLEOTIDES CONTAINING 5,6-DIHYDRO-5-AZACYTOSINE AND 5-AZACYTOSINE AT SPECIFIC CpG SITES

Amanda J. Goddard and Victor E. Marquez*
Laboratory of Medicinal Chemistry, Developmental
Therapeutics Program, Division of Cancer Treatment
National Cancer Institute, Bethesda, MD 20892

ABSTRACT: The quantitative conversion of dihydro-5-azacytosine (5-DHAC) to 5-azacytosine (5-AC) has been accomplished in a dihydro-5-azacytidine/thymidine dimer (5-DHAC_pT). This newly developed procedure allows similar possibilities with longer, 5-DHAC-modified oligodeoxynucleotides.

The hydrolytic instability of the triazine ring in 5-azacytosine (5-AC)-containing nucleosides is very well documented^{1,2} and hence use of a conventional phosphoramidite of 2'-deoxy-5-azacytidine in DNA synthesis would be impractical. We have recently reported the synthesis of a hydrolytically stable 2'-deoxy-5,6-dihydro-5-azacytidine phosphoramidite reagent (**1**) that gives excellent coupling yields in the construction of dihydro-5-azacytosine (5-DHAC)-containing oligodeoxynucleotides.³ However, the final objective of our investigation is the conversion of the incorporated 5-DHAC moiety into the corresponding 5-AC base. It is anticipated that these oligodeoxynucleotide fragments containing the modified cytosine base (5-AC), at specific CpG sites, will serve as biological tools capable of defining the mechanism of inhibition of DNA methyltransferase and the role that such inhibition plays in the regulation of gene expression.⁴





Scheme 1

Preliminary experiments towards the conversion of 5-DHAC to 5-AC have been conducted with dimer 2, which was prepared through the coupling of 1 to 3'-O-acetyl-thymidine.³ With this dimer it is very simple to monitor the extent of oxidation of the 5-DHAC base by observing the changes in the ratio of the m/z 531 to 533 peaks in the negative ion FAB/MS.

Since we anticipated using significant amounts of this dimer in optimizing the conditions for the 5-DHAC to 5-AC conversion, and we wanted to reserve the phosphoramidite 1 for the synthesis of larger oligodeoxynucleotides, an alternative synthesis for 2 was developed (Scheme 1). Thus, starting with thymidine, the 5'-phosphoramidite intermediate 4 was prepared and coupled to the dimethoxytrityl protected 5-aza-deoxycytidine riboside 3 to give dimer 5. This 5-AC-containing dimer was readily reduced with sodium borohydride to the 5-DHAC dimer 6, which, after removal of the protecting groups, produced 2 which was identical to the material obtained when 1 was used as a reagent.




Fig. 1. Fragmentation pattern for dimer 7 obtained by negative ion FAB mass spectroscopy

In our initial attempts to oxidize the 5-DHAC moiety in dimer 2, the silylation-mediated oxidation procedure for the aromatization of dihydrotriazine nucleosides^{5,6} produced only 34% yields of the desired dimer 7.³ Since this oxygen-dependent, radical oxidation requires the complete silylation of the substrate,⁵ it was possible that the reagent used, bis(trimethylsilyl)trifluoroacetamide (BSTFA), failed to form the requisite trimethylsilyl ester with the unsubstituted phosphate hydroxyl group 2 (ammonium salt). The use of trimethylsilyl chloride, in combination with BSTFA, overcame this difficulty by readily silylating the $P-O^- NH_4^+$ linkage. This allowed the reaction to proceed quantitatively as indicated by the FAB/MS of the desired dimer 7 (Fig. 1). In addition to the expected m/z 531 (100%) peak, it is interesting to observe the m/z 549 peak which corresponds to either the hydrated form of 5-AC or its open tautomer, N-formylguanyl urea. Similar hydrated forms have been detected to exist in equilibrium in aqueous solution of triazine nucleosides.^{1,2}

A key intermediate postulated in this oxygen-dependent oxidation reaction is trimethylsilyl peroxide.⁵ Since dissolved oxygen could be a limiting reagent, we synthesized this putative intermediate⁷ and used it as an additional reagent in our reaction mixture. Although the conversion of 2 to 7 appeared to have been completed in a shorter time, a detailed kinetic analysis of this reaction deserves further investigation.

Use of 1 in the preparation of 5-DHAC modified 26mers at the indicated CpG sites (bold face), was also accomplished. The selection of the parent unmodified oligomer (5'-CCGGCCATTACGGATCCGTCCTGGGC-3') was based on its reported excellent substrate properties for DNA methyl-transferase.⁸ Conversion of the 5-DHAC moiety into the 5-AC base in these oligomers is currently under investigation.

Acknowledgement: We would like to thank Dr. James A. Kelley for his help with the mass spectrometry.

REFERENCES

1. Lin, K.T.; Monparler, R.L.; Rivard, L.G.E. J. Phar. Sci. 1981, 70, 1228.
2. Beisler, J.A. J. Med. Chem. 1978, 21, 204.
3. Goddard, A.J.; Marquez, V.E. Tetrahedron Lett. 1988, 29, 1767.
4. Jones, P.A. Pharmac. Ther. 1988, 28, 17.
5. Kelley, J.A.; Abbasi, M.M.; Beisler, J. A. Anal. Biochem. 1980, 103, 210.
6. Beisler, J.A.; Abbasi, M.M.; Driscoll, J.S. J. Med. Chem. 1979, 22, 1230.
7. Cookson, P.G.; Davies, A.G.; Fazal, N. J. Organometal. Chem. 1975, 99, C31.
8. Bolden, A.H.; Nalin, C.M.; Ward, C.A.; Poonian, M.S.; McComas, W.W.; Weissbach, A. Nucleic Acids Res. 1985, 13, 3479.